drugset / Trial / NCT02605044

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

NCT02605044

Phase 3 Terminated 123 enrolled AB Science
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.

Timeline

Start
2014-01
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Masitinib Small molecule
Background Irinotecan Small molecule
Background Leucovorin Small molecule
Background fluorouracil Small molecule

Indications